Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19:141–54.

Article  CAS  PubMed  Google Scholar 

WHO. WHO coronavirus (COVID-19) dashboard. 2023.

Noh JY, Jeong HW, Shin E-C. SARS-CoV-2 mutations, vaccines, and immunity: implication of variants of concern. Signal Transduct Target Ther. 2021;6:203.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zahradník J, Marciano S, Shemesh M, Zoler E, Chiaravalli J, Meyer B, et al. SARS-CoV-2 RBD <em>in vitro</em> evolution follows contagious mutation spread, yet generates an able infection inhibitor. bioRxiv : the preprint server for biology. 2021:2021.01.06.425392.

Kemp SA, Meng B, Ferriera IATM, Datir R, Harvey WT, Papa G, et al. Recurrent emergence and transmission of a SARS-CoV-2 spike deletion H69/V70. bioRxiv : the preprint server for biology. 2021:2020.12.14.422555.

Planas D, Bruel T, Grzelak L, Guivel-Benhassine F, Staropoli I, Porrot F, et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nature Medicine. 2021;27:917–24.

Ahmad A, Fawaz MAM, Aisha A. A comparative overview of SARS-CoV-2 and its variants of concern. Infez Med. 2022;30:328–43.

CAS  PubMed  PubMed Central  Google Scholar 

ECDC. SARS-CoV-2 variants of concern as of 15 March 2024. 2024.

WHO. Tracking SARS-CoV-2 variants. 2024.

EMA. Spikevax (previously COVID-19 Vaccine Moderna). 2023.

FDA. Moderna COVID-19 Vaccine. 2023.

EMA. Comirnaty. 2023.

Pfizer. Pfizer and BioNTech Submit Applications to U.S. FDA for Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine. 2023.

Su YW, Qiu YZ, Wang YH, Xu Y, Huang CC, Zhang Q, et al. Safety and immunogenicity of heterologous boosting with a bivalent SARS-CoV-2 mRNA vaccine (XBB.1.5/BQ.1) in Chinese participants aged 18 years or more: A randomised, double-blinded, active-controlled phase 1 trial. Vaccine. 2024;42:2438–47.

Article  CAS  PubMed  Google Scholar 

CSPC. CSPC's COVID-19 mRNA vaccine included in emergency use in China. 2023.

Liu X, Sun Z, Wang Z, Chen J, Wu Q, Zheng Y, et al. Safety, immunogenicity, and efficacy of an mRNA COVID-19 vaccine (RQ3013) given as the fourth booster following three doses of inactivated vaccines: a double-blinded, randomised, controlled, phase 3b trial. eClinicalMedicine. 2023;64:102231.

Article  PubMed  PubMed Central  Google Scholar 

Li JX, Wu SP, Guo XL, Tang R, Huang BY, Chen XQ, et al. Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial. Lancet Respir Med. 2022;10:739–48.

Article  CAS  PubMed  PubMed Central  Google Scholar 

EMA. Nuvaxovid. 2023.

FDA. Novavax COVID-19 Vaccine, Adjuvanted (2023–2024 Formula) Authorized For Individuals 12 Years of Age and Older. 2023.

BioSpace. China Approves the World's First Vaccine against XBB Descendent Lineages of SARS-CoV-2 for Emergency Use. 2023.

Screener M. Livzon MABPharm Inc. Announces the Inclusion of Recombinant SARS-COV-2 Bivalent (Original/Omicron XBB) Fusion Protein Vaccine (Cho Cell) for Emergency Use. 2023.

Pollet J, Chen WH, Strych U. Recombinant protein vaccines, a proven approach against coronavirus pandemics. Adv Drug Deliv Rev. 2021;170:71–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lim HX, Arip M, Yahaya AAA, Jazayeri SD, Poppema S, Poh CL. Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials. Front Biosci (Landmark edition). 2021;26:1286–304.

Article  CAS  Google Scholar 

Puranik A, Lenehan PJ, Silvert E, Niesen MJM, Corchado-Garcia J, O’Horo JC, et al. Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence. MedRxiv Preprint Server Health Sci. 2021;383:1920.

Google Scholar 

Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet. 2021;397:99–111.

Article  CAS  Google Scholar 

Zhang Y, Belayachi J, Yang Y, Fu Q, Rodewald L, Li H, et al. Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco. BMC Public Health. 2022;22:1584.

Article  PubMed  PubMed Central  Google Scholar 

Collier DA, De Marco A, Ferreira I, Meng B, Datir RP, Walls AC, et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature. 2021;593:136–41.

Article  CAS  PubMed  Google Scholar 

Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. New England J Med. 2021;384:1885–98.

Article  CAS  Google Scholar 

Wu K, Werner AP, Moliva JI, Koch M, Choi A, Stewart-Jones GBE, et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv. 2021;586:567.

Google Scholar 

Cele S, Jackson L, Khoury DS, Khan K, Moyo-Gwete T, Tegally H, et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature. 2022;602:654–6.

Article  CAS  PubMed  Google Scholar 

Cheng SMS, Mok CKP, Leung YWY, Ng SS, Chan KCK, Ko FW, et al. Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination. Nat Med. 2022;28:486–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moghimi SM. Allergic reactions and anaphylaxis to LNP-based COVID-19 vaccines. Mol Ther. 2021;29:898–900.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Krishna M, Nadler SG. Immunogenicity to biotherapeutics–the role of anti-drug immune complexes. Front Immunol. 2016;7:21.

Article  PubMed  PubMed Central  Google Scholar 

Rayamajhi S, Rafi MA, Tripathi N, Dongol AS, Pandey M, Rayamajhi S, et al. Adverse events following immunization with ChAdOx1 nCoV-19 and BBIBP-CorV vaccine: A comparative study among healthcare professionals of Nepal. PLoS ONE. 2022;17:0272729.

Article  Google Scholar 

Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586:516–27.

Article  CAS  PubMed  Google Scholar 

Van Den Ende C, Marano C, Van Ahee A, Bunge EM, De Moerlooze L. The immunogenicity and safety of GSK’s recombinant hepatitis B vaccine in adults: a systematic review of 30 years of experience. Expert Rev Vaccines. 2017;16:811–32.

Article  PubMed  Google Scholar 

Ho JK, Jeevan-Raj B, Netter HJ. Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms. Viruses. 2020;12:126.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kulkarni PS, Raut SK, Patki PS, Phadke MA, Jadhav SS, Kapre SV, et al. Immunogenicity of a new, low-cost recombinant hepatitis B vaccine derived from Hansenula polymorpha in adults. Vaccine. 2006;24:3457–60.

Article  CAS  PubMed  Google Scholar 

Akuzum B, Kim S, Nguyen TT, Hong J, Lee S, Kim E, et al. L1 Recombinant proteins of HPV tested for antibody forming using sera of HPV quadrivalent vaccine. Immune Network. 2018;18:e19.

Article  PubMed  PubMed Central  Google Scholar 

EMA. Gardasil, INN-Human Papillomavirus Vaccine [Types 6, 11, 16, 18].

Buchanan TR, Graybill WS, Pierce JY. Morbidity and mortality of vulvar and vaginal cancers: Impact of 2-, 4-, and 9-valent HPV vaccines. Hum Vaccin Immunother. 2016;12:1352–6.

Article  PubMed  PubMed Central  Google Scholar 

Zhai L, Tumban E. Gardasil-9: A global survey of projected efficacy. Antiviral Res. 2016;130:101–9.

Article  CAS  PubMed  Google Scholar 

Monie A, Hung CF, Roden R, Wu TC. Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biol Targets Ther. 2008;2:97–105.

Google Scholar 

Cox MM, Izikson R, Post P, Dunkle L. Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults. Ther Adv vacc. 2015;3:97–108.

CAS  Google Scholar 

Dattwyler RJ, Gomes-Solecki M. The year that shaped the outcome of the OspA vaccine for human Lyme disease. 2022;7:10.

Google Scholar 

Comstedt P, Schüler W, Meinke A, Lundberg U. The novel Lyme borreliosis vaccine VLA15 shows broad protection against Borrelia species expressing six different OspA serotypes. PLoS ONE. 2017;12:e0184357.

Article  PubMed  PubMed Central  Google Scholar 

Azzari C, Bonanni P. A new meningococcal B vaccine for adolescents and adults: characteristics and methods of use. J Prev Med Hyg. 2018;59:E257–60.

CAS